Receptor-mediated internalization and degradation of urokinase is caused by its specific inhibitor PAI-1
- PMID: 2157592
- PMCID: PMC551782
- DOI: 10.1002/j.1460-2075.1990.tb08213.x
Receptor-mediated internalization and degradation of urokinase is caused by its specific inhibitor PAI-1
Abstract
The receptor for urokinase plasminogen activator (uPA) has been previously shown not to internalize its ligand, but rather to focalize its activity at the cell surface, allowing a regulated cell surface plasmin dependent proteolysis. The receptor in fact binds the proenzyme pro-uPA and allows its very efficient conversion to the active two chains form. Receptor bound active uPA can also interact with its specific type 1 inhibiror (PAI-1) which is therefore able to inhibit the cell surface plasmin formation. In this paper we show that the uPA-PAI-1 complex bound to the uPA receptor is internalized and degraded. U937 cells were incubated at 4 degrees C with labeled uPA-PAI-1 (and other ligands), the temperature then raised to 37 degrees C and the fate of the ligand followed for 3 h thereafter. The uPA-PAI-1 complex was internalized into the cells (i.e. could not be dissociated by acid treatment) and thereafter degraded (i.e. appeared in the supernatant in a non TCA-precipitable form). Other ligands (free uPA, ATF and DFP-treated uPA) were not internalized nor degraded. The degradation of the uPA-PAI-1 complex is preceded by internalization and is inhibited by chloroquine, an inhibitor of lysosomal protein degradation. These data suggest the existence of a cellular cycle of uPA. After synthesis pro-uPA is secreted, bound to the receptor and activated to two chain uPA. On the surface, uPA can activate surface bound plasminogen to produce surface bound plasmin. In the presence of PAI-1 uPA activity is inhibited and plasmin production interrupted, while the uPA-PAI-1 complex is internalized and degraded.
Similar articles
-
Internalization of the urokinase-plasminogen activator inhibitor type-1 complex is mediated by the urokinase receptor.J Biol Chem. 1992 May 5;267(13):9129-33. J Biol Chem. 1992. PMID: 1315748
-
Regions involved in binding of urokinase-type-1 inhibitor complex and pro-urokinase to the endocytic alpha 2-macroglobulin receptor/low density lipoprotein receptor-related protein. Evidence that the urokinase receptor protects pro-urokinase against binding to the endocytic receptor.J Biol Chem. 1994 Oct 14;269(41):25668-76. J Biol Chem. 1994. PMID: 7929271
-
Accessibility of receptor-bound urokinase to type-1 plasminogen activator inhibitor.Proc Natl Acad Sci U S A. 1989 Jul;86(13):4828-32. doi: 10.1073/pnas.86.13.4828. Proc Natl Acad Sci U S A. 1989. PMID: 2544876 Free PMC article.
-
Urokinase/urokinase receptor system: internalization/degradation of urokinase-serpin complexes: mechanism and regulation.Biol Chem Hoppe Seyler. 1995 Mar;376(3):143-55. Biol Chem Hoppe Seyler. 1995. PMID: 7612191 Review.
-
[Placenta accreta: epidemiology, molecular mechanism (hypothesis) and some clinical remarks].Ginekol Pol. 2004 Dec;75(12):971-8. Ginekol Pol. 2004. PMID: 15751221 Review. Polish.
Cited by
-
In vivo patterns of expression of urokinase and its inhibitor PAI-1 suggest a concerted role in regulating physiological angiogenesis.Proc Natl Acad Sci U S A. 1992 Nov 15;89(22):10686-90. doi: 10.1073/pnas.89.22.10686. Proc Natl Acad Sci U S A. 1992. PMID: 1279689 Free PMC article.
-
Immunohistochemical expressions of uPA and its receptor uPAR and their prognostic significant in urinary bladder carcinoma.Int Urol Nephrol. 2004;36(3):417-23. doi: 10.1007/s11255-004-8684-3. Int Urol Nephrol. 2004. PMID: 15783118
-
Bleomycin-induced pulmonary fibrosis in fibrinogen-null mice.J Clin Invest. 2000 Dec;106(11):1341-50. doi: 10.1172/JCI10531. J Clin Invest. 2000. PMID: 11104787 Free PMC article.
-
Transgenic mice demonstrate novel promoter regions for tissue-specific expression of the urokinase receptor gene.Am J Pathol. 2003 Aug;163(2):453-64. doi: 10.1016/S0002-9440(10)63675-9. Am J Pathol. 2003. PMID: 12875967 Free PMC article.
-
Selective growth inhibition of cancer cells by L-methioninase-containing fusion protein targeted to the urokinase receptor.Pharmacology. 2009;84(5):271-5. doi: 10.1159/000242997. Epub 2009 Oct 1. Pharmacology. 2009. PMID: 19797936 Free PMC article.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Miscellaneous